PAOG Takes Major CBD Pharmaceutical Development Step Forward
Sandusky, Ohio--(Newsfile Corp. - January 5, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced a major step forward in the development of a CBD pharmaceutical product.
- Sandusky, Ohio--(Newsfile Corp. - January 5, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced a major step forward in the development of a CBD pharmaceutical product.
- PAOG today announced an engagement with Veristat, Inc., a contract research organization headquartered in Southborough, Massachusetts.
- PAOG has engaged Veristat to assist in advancing PAOG with its proprietary Cannabidiol (CBD) extract for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) toward initiating an Investigational New Drug application (IND) with the Food and Drug Administration (FDA).
- With more than 26 years' experience in clinical trial planning and execution, Veristat is equipped to support any development program.